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ABSTRACT
Introduction: Hepatocellular carcinoma is one of the most common cancers that affected human in more than half of 
the world population. Although there is yet any alternatives treatment found for this disease, the antitumor property 
of thymoquinone has been well studied in most of cancer cell lines. Nonetheless, poor bioavailability of TQ limits its 
efficiency. The encapsulation form of TQ, TQ-NLC is suggested to enhance its bioavailability as well as cytotoxicity 
towards cancer cells via increasing resistance time and targeting drug to specified location in the body.  Therefore, 
it is a great advantage to look at the effects of TQ-NLC towards HepG2. This study is design to look at the anti-pro-
liferative effect of TQ-NLC on HepG2 and the changes in the cells morphology. Methods: Both cells were bought 
from ATCC and cultured in supplemented DMEM. Cell viability was determined via MTT assay. Pro-apoptotic effect 
of TQ-NLC was further confirmed with Annexin V staining. Morphology hallmarks of apoptosis of treated cells were 
also analysed using inverted microscope. Images were captured at 24, 48 and 72 hours. Results: TQ-NLC was very 
potent towards HepG2 compared to 3T3 with the relative IC
50
 of 25 µM. TQ-NLC was also more potent compared 
to the non-encapsulated form, TQ. Further analysis confirmed that TQ-NLC capable to increase the percentage 
of apoptotic cells in time-dependent manner. Qualitatively, all treated cells displayed the apoptosis morphology 
with increasing concentration and longer time-point. Conclusion: TQ-NLC showed greater cytotoxic effects towards 
HepG2 which was further confirmed with the morphological analysis.  
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INTRODUCTION
Cancer occurs when there is mutation or dysregulation 
in cell structures that lead to the detachment of primary 
tumor and amplified the distribution potential causing 
the metastatic spread of cancer cells to the secondary site 
throughout the body (15). Cancer cells able to develop 
proliferative signaling by their own producing growth 
factor ligands which can react via cognate receptors 
expression that lead to the autocrine proliferative 
stimulation (20). Notably, these growth factors are also 
responsible for the angiogenesis that supply sufficient 
oxygen and nutrients in order to support the tumor 
growth as well as metastasis (5). 
Hepatocellular carcinoma (HCC) is the sixth most 
common cancer affecting human in the world which 
is the third leading cause of cancer-related death (28). 
HCC is the main histological subtype among all types 
of primary liver cancers, about 70%– 85% of the total 
liver cancer worldwide (27). The incidence of HCC is 
arising annually with 75,000 cases worldwide (16). In 
Asia, there is a shift in the epidemiology of HCC. The 
age-standardized rates (ASR) of HCC in 2012 for males 
in Eastern Asia were 31.9 per 100,000 when compared 
to 2008 with the rates of 35.5 per 100,000 (11, 16).
In a study of natural compounds, herbal plants become 
valuable sources for new drugs since the conventional 
medicine carry some side effects to the body. Hence, 
the usage of natural compound with pharmacological 
properties as a substitution of the synthetic drugs has 
been escalated recently (9). The broad application of 
natural medicine has influenced the scientists to further 
scrutinize the presence of their active ingredient as well 
as the effects on human health in protecting cells from 
abnormalities (2). Amongst the favorable medicinal 
plants is Nigella sativa, the annual flowering plant that 
contains 5 to 10 petals, pink-purplish in color. The seed 
from Nigella could produce an essential (volatile) oil that 
contains bioactive compounds. Chemical composition 
of the compounds is very diverse and entails a range 
of dissimilar components comprising carbohydrates, 
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proteins, fats, oils and alkaloids (9, 12).   
The most abundant constituent of an essential (volatile) 
oil of N.sativa seeds is thymoquinone (TQ). Although 
TQ has been reported with the ability to eradicate 
cancer cells and hinder any modification in the genetic 
material of normal cells, it also has been shown to have 
poor bioavailability for in vivo test (12). TQ also has 
limited bioavailability and the solubility of pure TQ 
is relatively low in water (4). Therefore, a lipid nano-
carrier has been developed to overcome this problem. 
TQ loaded with nano-structured lipid carrier or TQ 
NLC has a potential used as an alternatives carrier for 
TQ compound. In pharmaceutical industry, NLC has 
been applied for topical purposes, oral and parenteral 
administration drugs as well as helping in increasing the 
bio-administration of natural compound (1). 
Therefore, this study is design to look at the anti-
proliferative effect of TQ-NLC on HepG2 and the 
changes in the cells morphology upon treatment.
 
MATERIALS AND METHODS
Chemical and reagents.
Dulbecco’s Modified Eagle’s Medium (DMEM), trypsin-
EDTA, antibiotics (penicillin and streptomycin), 3-(4, 
5-dimethylthiazol-2-yl)-2, 5-di-phenyltetrazolium 
bromide (MTT) powder, and trypan blue dye solution 
were purchased from Nacalai Tesque (Kyoto, Japan). 
Dimethyl sulfoxide (DMSO) was purchased from Fisher 
Sc. (UK) and the phosphate buffer saline tablet was 
purchased from Oxoid (England). Fetal Bovine Serum 
(FBS) was purchased from iDNA (South America Origin). 
Propidium iodide was purchased from Sigma (St. Louis, 
USA). TQ and TQ-NLC were provided by Assoc. Prof. 
Dr. Latifah Saiful Yazan, Laboratory of Molecular 
Biomedicine, Institute of Bioscience (IBS), Universiti 
Putra Malaysia.
Cell lines 
Human liver cancer cells, HepG2 and a normal skin 
fibroblast cell line (3T3) were purchased from the 
American Type Culture Collection (ATCC), USA. The 
cells were cultured in a complete DMEM medium and 
incubated at 37oC in an atmosphere containing 5%CO
2
.
Growth Inhibition Assay
Cytotoxicity effect of TQ-NLC or TQ on HepG2 and 3T3 
cells were determined by MTT assay in accordance to 
Tao et al. (30) with some modifications. Briefly, 4.0 X 
104 cells were seeded onto a 96-well plate in 0.05 mL 
completes DMEM medium. After overnight incubation 
for cell attachment, TQ-NLC at various concentrations 
(0.78 µM to 50 µM) were added to the culture medium. 
A control without treatment was also included. TQ was 
also added as a parental comparison while cisplatin 
acts as positive control. The assay was later terminated 
at 24, 48, and 72 hours and the ‘relative cell growth’ 
was measured by MTT assay. After incubation, the 
MTT solution (5 mg/mL) were added into each well. 
Absorbance was set at 570 nm and the reference 
wavelength of 630 nm was measured using a micro 
plate reader (Opsys MR, USA) (21).
Detection of mode of cell death
Cell death induced by TQ-NLC or TQ was detected using 
the FITC-Annexin V Apoptosis Detection Kits II (BD 
Biosciences) following the manufacturer’s instruction. 
Briefly, 1.0 X 105 cells were seeded with 3 mL media 
in a 6-well plate. After overnight incubation, the cells 
were treated with TQ-NLC or TQ and incubated again 
for 24, 48, and 72 hours. Cisplatin at 25 µM acts as a 
positive control. The cells were harvested and 100 µL 
of the cells were transferred into 5 mL FACS tubes. The 
cells were washed twice with cold PBS, and centrifuged 
at 486 x g for 5 minutes. A Master Mix containing 300 
µL of binding buffer, 2.5 µL of 50 µg/mL PI, and 1.25 
µL of Annexin V-FITC for each sample was prepared in 
the dark and 300 µL of the mixture was then added into 
each sample. The cells were incubated for 15 minutes 
at room temperature in the dark prior to flow cytometry 
analysis using the FL1 channel on a BD Biosciences 
FACSCalibur.
Cell morphology
Based on previous report by Ng et al. (25) with some 
modifications, changes in the treated cell morphology 
were observed under inverted microscope. HepG2 were 
treated in a 6-well plate with selected concentrations 
of TQ-NLC obtained from MTT assay. Untreated cell 
acts as a control. Cells were left to be incubated at 37oC 
and 5% CO
2
 for 24, 48 and 72 hours. Morphological 
changes of treated cells were observed and recorded. 
RESULTS
Cytotoxic effect of TQ-NLC or TQ on human liver 
cancer, HepG2.
Table I shows the anti-proliferative effects of TQ-NLC 
on the growth of HepG2 and 3T3 by MTT assay when 
exposed to various concentrations. DMSO and NLC 
act as negative control. TQ is added as a comparison 
of parental compound. Although TQ was less sensitive 
towards HepG2 compared to 3T3, TQ-NLC effect 
towards HepG2 was opposite with IC
50
 value of ~25 µM 
when exposed to various concentrations (Table I). Both 
compounds also showed non-cytotoxic selective effect 
towards normal 3T3 with overall IC
50
 values > 35µM. 
Meanwhile, both of the positive and negative control; 
cisplatin and NLC was observed to have minimum 
inhibitory effects in HepG2 and 3T3 with IC
50
 > 50µM.
TQ-NLC induced apoptosis in HepG2
To investigate in more detail the effects of TQ-NLC on 
HepG2, the percentage of cells death via apoptosis 
were analyzed using Annexin V staining at 24, 48 and 
72 hours of post-treatment with 25 µM of TQ-NLC 
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(Table II). Annexin V-FITC has high affinity to bind to 
phosphatidylserine (PS). Exposure of PS at the external 
surface of plasma membrane enables the binding of 
Annexin V that has been conjugated with FITC to the 
negatively charged PS. Data obtained showed that TQ-
NLC significantly reduced the percentage of viable 
HepG2 (~82-85%) with p< 0.01 and increased the 
percentage of apoptotic cells (~12-13%) after 24, 48 
and 72 hours of treatment compared to control (Fig. 
1). Although cisplatin also demonstrated a significant 
reduction in healthy HepG2 (p<0.05), TQ-NLC showed 
a more potent effect with lesser viable cells compared to 
the positive control (p<0.01). 
Figure 1: Quantitation of apoptosis in HepG2 cells treated with NLC, 
and TQNLC for indicated time points (24, 48 and 72 hours). AV-/PI-
(BLUE), AV+/PI-(ORANGE), AV+/PI+ (GREY) and AV-/PI+ (YELLO\V). 
Data shown are the average of three independent experiments. Statis-
tically significant is noted as (*p<0.05), (**p<0.0I) and (***p<0.00I).
Table 1: Cytotoxic effects of TQNLC or TQ on HepG2 and 3T3 reflected by the IC
50
 values determined from the MTT assay.
Cell line
Incubation time 
(hour)
IC
50
 (µM)
TQ-NLC TQ DMSO CISPLATIN NLC
HepG2 24 25.8±1.82 49.3±2.24 NP NP NP
48 23.8±3.41 41.9±0.44 NP NP NP
72 23.1±6.24 40.7±2.47 >50 >50 >50
3T3 24 41.2±0.25 46.7±1.14 NP NP NP
48 38.7±1.55 38.9±2.88 NP NP NP
72 39.2±0.84 39.1±0.96 >50 >50 >50
Table II: Percentage of viable, apoptotic and necrotic cells as deter-
mined via flow cytometry.
Percentage of cell (%)
Viable 
Cell
Early 
apoptosis
Late 
apoptosis
Necrosis
UNTREATED 95.9 1.7 1.2 1.2
NLC 94.7 2.2 1.9 1.3
Cisplatin 87.4 5.5 4.7 2.5
TQ-NLC (24h) 85.2 7.4 4.9 2.3
TQ-NLC (48h) 84.6 7.9 5.3 2.3
TQ-NLC (72h) 82.2 7.5 6.1 4.3
Percentage of viable cell computed in comparison to the untreated cells which has been 
calculated as 100%. Each value represented as mean ±SEM. NP, not performed. Notes: * 
compare to control with p<0.05
Morphological changes of HepG2 upon treatment with 
TQ-NLC
Treatment with designated concentrations of TQ-NLC 
(12.5 µM and 25 µM) showed significant morphological 
changes in HepG2 compared to control after 24, 48 and 
72 hours incubation (Fig.2). Concentration of 12.5 µM 
was chosen to see if half of the concentrated toxicity 
have any effects on the treated cells morphology. 
Interestingly, at lower concentration, treated cells 
remain attached at the substratum after 24 hours 
treatment. Although some cells had detached and 
undergoing cell shrinkage at 48 hours, the present of 
apoptotic bodies were only recorded after 72 hours 
treatment. Meanwhile, at higher concentrations, more 
cells underwent membrane blebbing as early as 48 
hours followed by apoptotic bodies. At 72 hours, 
more apoptotic bodies were observed compared to the 
control. The reduced number of cells population was 
prominent with increasing concentration of TQ-NLC 
and longer incubation period. Cells morphology was 
observed using an inverted microscope. 
DISCUSSION
Traditionally, plants or plant extracts are important 
source of remedies that rich in natural compounds used 
to treat a wide variety of diseases. However, most of 
the compounds have not been discovered until today 
and the biodiversity of plants represent indefinite source 
of novel chemical compounds. To date, about 60% of 
the discovered anticancer agents including paclitaxel, 
vinblastine and vincristine are attained from plants (7). 
Thymoquinone (TQ), an active lipophilic compound 
found in Nigella sativa plant has a variation of pharma-
cological properties such as anticancer effects in diverse 
human cancer (3, 13).
However, due to the poor bioavailability of TQ, Ng et al, 
(24) had designated and effectively prepared thymoqui-
none loaded nanostructured lipid carrier (TQ-NLC) via 
high-pressure homogenization technique. The encapsu-
lation of TQ in NLC has increased drug efficiency and 
controlled drug release (24). NLC has been established 
to transport drugs to several application routes including 
topical skin delivery, parenteral injection, ocular deliv-
ery, oral administration and pulmonary inhalation (10). 
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Figure 2: Morphological changes of TQNLC-treated HepG2 observed wider an inverted light microscope (40X magnifications). Cell popu-
lation decreased in a concentration and time dependent. All treated cells showed apoptotic characteristics such as cellular detached (de), cell 
shrinkage (cs) and membrane blebbing (mb). Formation of apoptotic bodies is being labelled as ab. Healthy cells which remained attached at 
the surface of the flask is labelled as attached cells (ac). 
It is particularly useful for targeting water-soluble drug 
administration. 
Lipid-based drug delivery systems are promising oral 
carriers due to their ability to enhance oral bioavailabil-
ity and increase the solubility of poorly water-soluble 
and lipophilic drugs (17). NLC comprises of a biocom-
patible solid lipid matrix entangling a liquid lipid as na-
no-compartments that enhanced drug loading capacity 
with greater physical stability and preventing drug leak-
age during storage (23, 29). Moreover, NLC particles 
could evade liver metabolism through the formation of 
micelles with bile salts in the small intestines after they 
entered the gastrointestinal (GI) tract (19). Based on the 
previous acute toxicity study (26), encapsulation of TQ 
in NLC reduces the toxic effect of the compound which 
provide safety information for TQ-NLC, which is import-
ant for further study in clinical use. TQ-NLC has been 
well demonstrated to be more cytotoxic towards breast 
cancer, MDA-MB-231 and MCF7 cells as well as cervi-
cal cancer SiHa cells compared to TQ (8, 24). Although 
there was a report on the effect of TQ towards HepG2 
cells, no study has been conducted to look at the toxici-
ty effects of TQ-NLC towards liver cancer cells, HepG2. 
HepG2 is a non-tumorigenic cells with hepatitis B virus 
negative and express majority of drug-metabolizing en-
zymes (6). Our data showed that TQ-NLC is more toxic 
towards HepG2 compared to TQ. Similarly, TQ-NLC 
was also observed to be more toxic compared to TQ 
in Hep3B cells (14). This has been suggested due to the 
encapsulated form of TQ that contribute to the differ-
ential effect as it has been improved in bioavailability 
and cytotoxicity (14). Nevertheless, TQ-NLC is less toxic 
towards normal 3T3 cells with IC
50
 > 30 µM (15, 24). 
Similar cytotoxic selective effect of TQ-NLC was also 
observed towards normal cells 3T3-L1 and Vero cells 
after 72 hours treatment with IC
50
 values of  >50 µM and 
32 µM respectively (18, 25).
Further analysis to confirm the vulnerability of HepG2 
towards TQ-NLC at selected concentration was per-
formed using Annexin V staining. A concentration was 
chosen based on the IC
50
 value obtained from MTT as-
say. The result (Table II) demonstrated significant reduc-
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tion in the percentage of healthy cells (~82-85%) and in-
creased in the percentage of apoptotic cells (~12-13%) 
in time dependent compared to the untreated (Fig. 1). 
TQ-NLC was also demonstrated to be more cytotoxic 
compared to cisplatin which acts as a positive control. 
This confirmed that TQ-NLC caused the sensitivity and 
increased the vulnerability of HepG2 upon treatment. 
Previous studies had also demonstrated that TQ-NLC 
reduced the viability of several other cancer cells such 
MDA-MB-231 (24) and Hep3B (14). Although exact 
mechanism has not been fully elucidated, it is suggested 
that TQ-NLC may trigger cell death via apoptosis. 
Cancerous cells are well-known to evade apoptosis. 
Apoptosis is a physiological response to eliminate un-
wanted or dysfunctional cells as well as to maintain ho-
meostatic balance. In HepG2 treated TQ-NLC, features 
of apoptosis such as detachment of cells from substra-
tum, cells shrinkage, membrane blebbing and formation 
of apoptotic bodies as reported by Zhuang et al. (31) 
were observed in concentration and time-dependent 
manner. At higher dosage of 25 µM, more treated cells 
were deformed and demonstrated morphologic hall-
mark of apoptosis. Number of apoptotic bodies were 
increased after 72 hours of treatment. These will later be 
phagocytosed by the neighboring cells such as paren-
chymal and macrophages cells. Hence, this shows that 
TQ-NLC is able to induce apoptosis in HepG2. Similar 
apoptotic features was also recorded in MDA-MB-231 
treated TQ-NLC (24). Although not many studies had 
been conducted to look at the anti-apoptotic effect of 
TQ-NLC, the classical sign of apoptosis such as chro-
matin condensation, translocation of phosphatidyl ser-
ine across plasma membrane and fragmentation of DNA 
have also been observed in TQ-treated cells (4). TQ-
NLC is also suggested to have improved pro-apoptot-
ic effect due to the high encapsulation efficiency and 
drug loading capacity. The improved effect of TQ-NLC 
has been reported previously by Haron et al. (14) that 
demonstrated better apoptotic effect promoted by TQ-
NLC compared to TQ itself. 
CONCLUSION
Our data provide important preliminary insights on 
the effect of TQ-NLC towards HepG2 which can be 
an effective anti-proliferative agent of liver cancer. 
Our finding showed that TQ-NLC able to inhibit the 
proliferation of HepG2 which was further confirmed 
with the Annexin V staining and the presence of 
apoptotic hallmark in the morphology of treated cells. 
However, further molecular investigations are needed to 
explicitly map out the mechanism involved in triggering 
the apoptosis. 
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